Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006022 · ClinicalTrials.gov registry record · Phase 1
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00006022 is a Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 17 participants.
The verdict
NCT00006022, a Phase 1 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining bryostatin 1 with interleukin-2 may kill more tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of interleukin-2 plus bryostatin 1 in treating patients who have melanoma or kidney cancer that cannot be removed during surgery.
Interventions
- BIOLOGICAL aldesleukin
- DRUG bryostatin 1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2000-09 |
| Est. Completion | 2004-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006022
The ClinicalTrials.gov registry entry for NCT00006022 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which aldesleukin is the first listed.
NCT00006022 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006022 about?
NCT00006022 is a clinical study titled "Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining bryostatin 1 with interleukin-2 may kill more tumor cells. PURPOSE: Randomized phase I tria...
What is the current status of trial NCT00006022?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2000-09. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00006022?
The interventions under investigation include: aldesleukin (BIOLOGICAL), bryostatin 1 (DRUG).
Who is sponsoring clinical trial NCT00006022?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.